NEWTON, Mass., March 01, 2021 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs, today announced that Acer’s management team will present and host one-on-one investor meetings at the upcoming H.C. Wainwright Global Life Sciences Virtual Conference and the 33rd Annual Roth Virtual Conference.
|Conference:||H.C. Wainwright Global Life Sciences Virtual Conference|
|Dates:||March 9-10, 2021|
|Format:||One-on-one virtual meetings|
|Conference:||33rd Annual Roth Virtual Conference|
|Format:||Panel Presentation and one-on-one virtual meetings|
|Panel:||Therapeutics Against SARS-CoV-2|
|Date:||Monday, March 15, 2021|
|Time:||12 p.m. Eastern Time|
About Acer Therapeutics Inc.
Acer is a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs. Acer’s pipeline includes four programs: ACER-001 (sodium phenylbutyrate) for the treatment of various inborn errors of metabolism, including urea cycle disorders (UCDs) and Maple Syrup Urine Disease (MSUD); EDSIVO™ (celiprolol) for the treatment of vascular Ehlers-Danlos syndrome (vEDS) in patients with a confirmed type III collagen (COL3A1) mutation; ACER-801 (osanetant) for the treatment of induced Vasomotor Symptoms (iVMS); and ACER-2820 (emetine), a host-directed therapy against a variety of infectious diseases, including COVID-19. Each of Acer’s product candidates is believed to present a comparatively de-risked profile, having one or more of a favorable safety profile, clinical proof-of-concept data, mechanistic differentiation and/or accelerated paths for development through specific programs and procedures established by the FDA. For more information, visit www.acertx.com.
Acer Therapeutics Inc.